BioCentury | Nov 18, 2020
Product Development

Nov. 17 Quick Takes: Phase III miss for BrainStorm’s ALS program; plus Novo, BioMarin-Deep Genomics, Lexicon, Seed-Lilly and RhoVac

BrainStorm sees path forward for ALS therapy despite Phase III missBrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) shed $7.92 (66%) to $4.02 on Tuesday after its mesenchymal stem cell therapy NurOwn missed the primary endpoint in a...
BioCentury | Nov 6, 2020
Deals

With $1.4B Emisphere buy, Novo gets delivery tech used in Rybelsus

With its takeout of Emisphere, Novo will gain control of an oral drug delivery technology it has already used in a product crucial to its future, while also buying out that drug’s royalty stream. Novo...
BioCentury | Oct 16, 2020
Finance

VectivBio prepping pivotal GI trial with $110M crossover round that could presage IPO

A public listing could be VectivBio’s next financial step now that it has raised $110 million in a crossover round that will fund its planned Phase III trial in short bowel syndrome, as well as...
BioCentury | Sep 30, 2020
Distillery Therapeutics

An FGF21, GLP-1 fusion protein for diabetes, obesity

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Diabetes; obesity A fusion protein comprising FGF21 and GLP-1 analogs linked by an elastin-like polypeptide could treat diabetes and obesity. In HEK cells, the fusion protein agonized the FGF21 receptor complex...
BioCentury | Sep 30, 2020
Distillery Therapeutics

Endogenous bile acid identified for obesity and diabetes

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity; diabetes GPBAR1 agonism via cholic acid-7-sulfate, a gut-restricted endogenous bile acid, could treat obesity and Type II diabetes. In people who had undergone sleeve gastronomy, post-surgery fecal samples had higher levels...
BioCentury | Sep 30, 2020
Product Development

Partner Amgen becomes investor as Carmot pushes diabetes therapies ahead with $47M series C

Amgen has joined the syndicate of investors backing Carmot in a $47 million series C round that will advance its lead Type II diabetes candidate — a therapy developed using the same platform that spawned...
BioCentury | Sep 25, 2020
Product Development

Novo makes obesity pick as amylin/GLP-1 combo promises gastric bypass-like efficacy

Novo Nordisk is closing in on a one-two punch it believes could shift the treatment paradigm for obesity with the pick of an amylin/semaglutide combination as its next big therapy in the disease. The combo...
BioCentury | Jul 10, 2020
Finance

How buysiders are sizing up commercial launches during the pandemic

Commercial launches were expected to be one of the biopharma activities hit hardest by the pandemic, but some new products have performed better than expected. The environment is not only pushing biotechs to new practices,...
BioCentury | Jun 19, 2020
Product Development

Hua shows sustained benefit in diabetics with glucokinase activator

Hua announced Phase III follow-up data showing its first-in-class diabetes therapy led to sustained HbA1c reductions at one year -- a long-term effect that EVP and CFO George Lin told BioCentury hasn’t been observed with...
BioCentury | Jun 11, 2020
Deals

With $725M Corvidia takeout, Novo gets clinical atherosclerosis asset

Novo Nordisk’s deal to acquire Corvidia for $725 million up front gives the Danish pharma a Phase IIb atherosclerosis asset that expands its range in cardiometabolic diseases adjacent to its core business of treating diabetes...
Items per page:
1 - 10 of 1307